Genetico’s Revenue Grows by 60% Over Two Years

GENETICO Center for Genetics and Reproductive Medicine (MOEX: GECO) has published its operating results for the 12 months of 2025, prepared in accordance with Russian Accounting Standards (RAS).

Genetico Center, a resident of Medtech Technopark, is part of the Artgen Biotech Group (MOEX: ABIO). The Company operates in the field of medical genetics and genetic research, implementing innovative solutions for the diagnosis, prevention, and treatment of genetic and socially significant diseases into healthcare practice.

In 2025, the Company's revenue grew by 30%. Total revenue growth over the last two years amounted to 59.8%, while gross profit grew by 10% over two years.

Following the repayment of its bond loan in June 2025, the Company has no debt capital.

Key Events in 2025:

The Board of Directors of Genetico appointed a new CEO — Igor Yuryevich Zharkikh;
The number of genetic tests increased by 20.5% and consultations by 5.4% compared to 2024;
In 2025, Genetico received a patent for the Onconetix panel for genetic testing of tumors and selection of targeted therapy for oncological diseases;
More than 62 objects of its own R&D related to PGT (preimplantation genetic testing) have been filed for registration of intellectual property rights. As of early 2026, Genetico Center has received 34 patents in the field of PGT, with 28 patent applications pending;
Genetico invests RUB 20 million in Retinostar, a developer of first-in-class gene therapy treatments for orphan eye diseases;
Genetico invests RUB 50 million in Cardiogenex, a developer of treatments for heart diseases;
Genetico fully repaid its bond loan in the amount of RUB 145 million;
Genetico's shares were admitted to trading on the SPB Exchange, including during the additional session;
Genetico completed a private placement of 7 million shares in favor of companies within the Artgen Biotech Group.

Key Indicators of P&L Statement

RUB, thousands	January - December 2025	January - December 2024	January - December 2023	Change, % 2025/2024	Change, % 2025/2023
Revenue	553 142	425 964	346 101	29,86%	59,82%
Cost of sales	-462 132	-332 454	-263 357	39,01%	75,48%
Gross profit (loss)	91 010	93 510	82 744	-2,67%	9,99%
Commercial expenses	-71 706	-53 064	-49 783	35,13%	44,04%
Management expenses	-54 574	-33 861	-48 104	61,17%	13,45%
Profit (loss) from sales	-35 270	6 585	-15 143	-635,61%	132,91%
Interest receivable	3 801	1 311	3 281	189,93%	15,85%
Interest payable	-7 419	-30 917	-28 601	-75,47%	-73,49%
Other income and (expenses), net	-27 179	9 728	5 294	-379,39%	-613,39%
Net profit (loss)	-66 067	-13 293	-35 169	-398,24%	88,32%
EBITDA¹	-31 104	48 980	29 048	-147,87%	-179,90%
EBITDA margin, %	-5,62%	11,50%	8,39%

¹ EBITDA — earnings before interest, taxes, depreciation and amortization. This indicator reflects the profit from operating activities of the Company available to creditors, investors, and founders.

Key balance sheet indicators in 2025

RUB, thousands	December 31, 2025	December 31, 2024	% change
ASSETS
Intangible assets + Fixed assets	645 247	658 580	-2,16%
Stocks	104 322	84 188	-12,06%
Accounts receivable	77 153	78 405	12,60%
Financial investments (excluding cash equivalents)	48 990	-	60,62%
Cash and cash equivalents	8 414	30 341	135,62%
TOTAL ASSETS	884 405	851 834	0,39%

LIABILITIES
Equity and reserves	772 308	613 668	28,61%
Long-term liabilities	32 029	87 840	-18,73%
Current liabilities	80 068	150 326	-67,89%
TOTAL LIABILITIES	884 405	851 834	0,39%

The financial statements of Genetico PJSC for 2025 under RAS are available on the corporate website at www.investors.genetico.ru